PTCT PTC THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, PTC THERAPEUTICS INC reported revenue of $361M (up 101.5% from a year earlier), net income of $83.5M and diluted EPS of $0.92; over the last four quarters revenue was $1.01B and net income −$38.0M; for the fiscal year ended December 2025 revenue was $1.73B, up 114.5% on the year before.

PTCT annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $1.73B, gross profit n/a, operating income $867M, net income $683M (margin 39.5%), EPS $7.78
• Fiscal year ended Dec 2024: revenue $807M, gross profit n/a, operating income −$303M, net income −$363M (margin -45.0%), EPS −$4.73
• Fiscal year ended Dec 2023: revenue $938M, gross profit n/a, operating income −$440M, net income −$627M (margin -66.8%), EPS −$8.37
• Fiscal year ended Dec 2022: revenue $699M, gross profit n/a, operating income −$447M, net income −$559M (margin -80.0%), EPS −$7.79
• Fiscal year ended Dec 2021: revenue $539M, gross profit n/a, operating income −$374M, net income −$524M (margin -97.3%), EPS −$7.43

PTCT quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $361M (up 101.5% year over year), net income $83.5M, EPS $0.92
• Quarter ended Mar 31, 2026: revenue $273M (down 76.8% year over year), net income −$2.81M, EPS −$0.03
• Quarter ended Dec 31, 2025 (from the annual report): revenue $165M (down 22.7% year over year), net income −$135M, EPS −$1.63
• Quarter ended Sep 30, 2025: revenue $211M (up 7.2% year over year), net income $15.9M, EPS $0.20
• Quarter ended Jun 30, 2025: revenue $179M (down 4.2% year over year), net income −$64.8M, EPS −$0.83
• Quarter ended Mar 31, 2025: revenue $1.18B (up 459.7% year over year), net income $867M, EPS $10.04
• Quarter ended Dec 31, 2024 (from the annual report): revenue $213M (down 30.6% year over year), net income −$65.9M, EPS −$0.85
• Quarter ended Sep 30, 2024: revenue $197M (up 0.1% year over year), net income −$107M, EPS −$1.39
• Quarter ended Jun 30, 2024: revenue $187M (down 12.7% year over year), net income −$99.2M, EPS −$1.29
• Quarter ended Mar 31, 2024: revenue $210M (down 4.7% year over year), net income −$91.6M, EPS −$1.20
• Quarter ended Dec 31, 2023 (from the annual report): revenue $307M (up 83.4% year over year), net income −$156M, EPS −$2.07
• Quarter ended Sep 30, 2023: revenue $197M (down 9.5% year over year), net income −$133M, EPS −$1.76
• Quarter ended Jun 30, 2023: revenue $214M (up 29.2% year over year), net income −$199M, EPS −$2.66
• Quarter ended Mar 31, 2023: revenue $220M (up 48.2% year over year), net income −$139M, EPS −$1.88
• Quarter ended Dec 31, 2022 (from the annual report): revenue $167M (up 1.3% year over year), net income −$171M, EPS −$2.35
• Quarter ended Sep 30, 2022: revenue $217M (up 56.5% year over year), net income −$109M, EPS −$1.53
• Quarter ended Jun 30, 2022: revenue $166M (up 41.9% year over year), net income −$152M, EPS −$2.13
• Quarter ended Mar 31, 2022: revenue $149M (up 26.1% year over year), net income −$127M, EPS −$1.78
• Quarter ended Dec 31, 2021 (from the annual report): revenue $165M, net income −$143M, EPS −$2.03
• Quarter ended Sep 30, 2021: revenue $139M, net income −$134M, EPS −$1.89

PTCT cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $711M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$108M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$158M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$357M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$251M, share buybacks n/a

PTCT balance sheet

• Jun 30, 2026: cash $1.05B, total assets $3.25B, total liabilities $3.42B, shareholders' equity −$165M, long-term debt $536M
• Mar 31, 2026: cash $834M, total assets $2.87B, total liabilities $3.05B, shareholders' equity −$180M
• Dec 31, 2025: cash $985M, total assets $2.90B, total liabilities $3.10B, shareholders' equity −$205M
• Sep 30, 2025: cash $673M, total assets $2.64B, total liabilities $2.80B, shareholders' equity −$156M
• Jun 30, 2025: cash $1.02B, total assets $2.63B, total liabilities $2.84B, shareholders' equity −$207M, long-term debt $286M
• Mar 31, 2025: cash $1.48B, total assets $2.66B, total liabilities $2.84B, shareholders' equity −$186M, long-term debt $286M
• Dec 31, 2024: cash $780M, total assets $1.71B, total liabilities $2.80B, shareholders' equity −$1.10B, long-term debt $285M
• Sep 30, 2024: cash $526M, total assets $1.84B, total liabilities $2.90B, shareholders' equity −$1.05B, long-term debt $285M

What is PTCT's revenue?

PTC THERAPEUTICS INC reported $1.01B of revenue over its last four quarters, through June 30, 2026.

Is PTCT profitable?

No. PTC THERAPEUTICS INC lost $38.0M over the last four quarters.

What is PTCT's EPS?

Diluted earnings per share over the last four quarters were −$0.54; $0.92 in the latest quarter.

PTCT ownership and insider trades · All stocks